Digital TIL Therapies Summit

Memo

Targeted immunotherapy and lymphocyte modifications have progressed therapeutically with an astounding speed and improved efficacy. Solid tumors, however, still remain a stubborn and viscous clinical target. TIL therapy, with the recent advances in industry and academia is finally moving into the forefront. There are huge milestones to hit, what do we identify, how do we manufacture, and can we accelerate the treatment process? By addressing what, when and how to treat, TIL Therapies Digital Summit brings together the leading giants in industry and academia to answer these most pressing questions. With 8 case studies crammed into one dynamic, digital day, take the opportunity to learn, network and advance your immunotherapeutic output. This digital summit brings together worldwide experts in TIL therapy at the other end of your computer. As the interest and developments in TIL therapy skyrocket and the solid tumor prevalence continues to creep up- understanding the limitations and targeting difficulties are key to solving this unmet medical demand. https://til-therapies.com/ 31 August, 20208.30am - 6.15pm EST | 5.30am - 3.15pm PST Contact:This email address is being protected from spambots. You need JavaScript enabled to view it. URLs:Brochure: https://go.evvnt.com/665693-0?pid=5569Tickets: https://go.evvnt.com/665693-2?pid=5569 Prices:Industry Pricing (Earlybird rates available): USD 1200.0,Academic Pricing (Earlybird rates available): USD 850.0 Speakers: Amod Sarnaik, Associate Professor of Cutaneous Oncology and Immunology, Moffit Cancer Centre, Kelly DiTrapani, Vice President, Medical Affairs, Iovance, Micah Benson, Head of Immunology, KSQ Therapeutics, Cyrille Cohen, Professor and Vice Dean at Faculty of Life Sciences, Bar-llan University, Linh Nguyen, Staff Scientist and Head of Cell Manufacturing Team, Princess Margaret Cancer Centre, Riikka Havunen, Head of Research And Development, TILT Biotherapeutics Time: 08:30 - 18:15